Recent advances in pulmonary arterial hypertension [version 1; referees: 2 approved]

Martin R. Wilkins*, Jurjan Aman, Lars Harbaum, Anna Ulrich, John Wharton, Christopher J. Rhodes

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Pulmonary arterial hypertension (PAH) is a rare disorder with a high mortality rate. Treatment options have improved in the last 20 years, but patients still die prematurely of right heart failure. Though rare, it is heterogeneous at the genetic and molecular level, and understanding and exploiting this is key to the development of more effective treatments. BMPR2, encoding bone morphogenetic receptor type 2, is the most commonly affected gene in both familial and non-familial PAH, but rare mutations have been identified in other genes. Transcriptomic, proteomic, and metabolomic studies looking for endophenotypes are under way. There is no shortage of candidate new drug targets for PAH, but the selection and prioritisation of these are challenges for the research community.

Original languageEnglish
Article number1128
JournalF1000Research
Volume7
DOIs
Publication statusPublished - 2018

Cite this